Martin L Sos

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3768759/publications.pdf

Version: 2024-02-01

55 papers	12,134 citations	94433 37 h-index	155660 55 g-index
56 all docs	56 docs citations	56 times ranked	18577 citing authors

#	Article	IF	Citations
1	Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009, 462, 108-112.	27.8	2,707
2	K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature, 2013, 503, 548-551.	27.8	1,713
3	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nature Genetics, 2012, 44, 1104-1110.	21.4	1,186
4	Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine, 2010, 2, 62ra93.	12.4	761
5	PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. Cancer Research, 2009, 69, 3256-3261.	0.9	480
6	Optimization of Dosing for EGFR-Mutant Nonâ€“Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	12.4	457
7	Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	9.4	455
8	MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell, 2017, 31, 270-285.	16.8	406
9	Differential Protein Stability and ALK Inhibitor Sensitivity of EML4-ALK Fusion Variants. Clinical Cancer Research, 2012, 18, 4682-4690.	7.0	252
10	Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 18351-18356.	7.1	251
11	Predicting drug susceptibility of nonâ€“small cell lung cancers based on genetic lesions. Journal of Clinical Investigation, 2009, 119, 1727-1740.	8.2	230
12	A Neo-Substrate that Amplifies Catalytic Activity of Parkinsonâ€™s-Disease-Related Kinase PINK1. Cell, 2013, 154, 737-747.	28.9	229
13	A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine, 2011, 17, 1504-1508.	30.7	224
14	Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors. Clinical Cancer Research, 2016, 22, 4837-4847.	7.0	223
15	Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation. Cancer Research, 2010, 70, 868-874.	0.9	191
16	ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors. Clinical Cancer Research, 2011, 17, 7394-7401.	7.0	179
17	K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology, 2019, 14, 606-616.	1.1	178
18	A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 17034-17039.	7.1	167

#	Article	IF	Citations
19	Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics. Clinical Cancer Research, 2015, 21, 2236-2243.	7.0	147
20	Characteristics of Lung Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2013, 19, 2584-2591.	7.0	134
21	New Approaches to SCLC Therapy: From the Laboratory to the Clinic. Journal of Thoracic Oncology, 2020, 15, 520-540.	1.1	119
22	Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Modern Pathology, 2012, 25, 1473-1480.	5.5	118
23	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. Nature Communications, 2018, 9, 4655.	12.8	107
24	Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. Journal of Medicinal Chemistry, 2015, 58, 6844-6863.	6.4	92
25	Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients. Journal of Thoracic Oncology, 2015, 10, 1049-1057.	1.1	85
26	Early Detection of Erlotinib Treatment Response in NSCLC by 3â€²-Deoxy-3â€²-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET). PLoS ONE, 2008, 3, e3908.	2.5	80
27	The next tier of EGFR resistance mutations in lung cancer. Oncogene, 2021, 40, 1-11.	5.9	77
28	Family matters: How MYC family oncogenes impact small cell lung cancer. Cell Cycle, 2017, 16, 1489-1498.	2.6	75
29	Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients. Clinical Cancer Research, 2018, 24, 1337-1343.	7.0	71
30	Oncogene Mimicry as a Mechanism of Primary Resistance to BRAF Inhibitors. Cell Reports, 2014, 8, 1037-1048.	6.4	69
31	Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes. Nature Communications, 2021, 12, 2048.	12.8	66
32	Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Science Translational Medicine, 2017, 9, .	12.4	55
33	Synthesis and Biological Evaluation of 4-Anilinoquinolines as Potent Inhibitors of Epidermal Growth Factor Receptor. Journal of Medicinal Chemistry, 2010, 53, 2892-2901.	6.4	54
34	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications, 2019, 10, 3485.	12.8	54
35	AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO Journal, 2012, 31, 3961-3975.	7.8	53
36	Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer. Clinical Cancer Research, 2017, 23, 5527-5536.	7.0	44

#	Article	IF	Citations
37	Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma. Cell Reports, 2017, 20, 2833-2845.	6.4	40
38	Discovery and functional characterization of a neomorphic PTEN mutation. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13976-13981.	7.1	38
39	Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. Journal of Thoracic Oncology, 2015, 10, e40-e43.	1.1	33
40	Staurosporine-Derived Inhibitors Broaden the Scope of Analog-Sensitive Kinase Technology. Journal of the American Chemical Society, 2013, 135, 18153-18159.	13.7	31
41	MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I. Nature Communications, 2021, 12, 5505.	12.8	30
42	Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling. PLoS ONE, 2010, 5, e8919.	2.5	24
43	Report of the First International Symposium on NUT Carcinoma. Clinical Cancer Research, 2022, 28, 2493-2505.	7.0	23
44	Inhibition of Nuclear Translocation of Nuclear Factor-Î¹B Despite Lack of Functional ÎºBÎ± Protein Overcomes Multiple Defects in Apoptosis Signaling in Human B-Cell Malignancies. Clinical Cancer Research, 2005, 11, 8186-8194.	7.0	19
45	Targeting Gain of Function and Resistance Mutations in Abl and KIT by Hybrid Compound Design. Journal of Medicinal Chemistry, 2013, 56, 5757-5772.	6.4	17
46	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
47	Sorafenib and everolimus in patients with advanced solid tumors and KRASâ€mutated NSCLC: A phase I trial with early pharmacodynamic FDGâ€PET assessment. Cancer Medicine, 2020, 9, 4991-5007.	2.8	14
48	Expression of Signaling Mediators Downstream of EGF-Receptor Predict Sensitivity to Small Molecule Inhibitors Directed Against the EGF-Receptor Pathway. Journal of Thoracic Oncology, 2008, 3, 170-173.	1.1	13
49	Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors. Journal of Medicinal Chemistry, 2022, 65, 6643-6655.	6.4	12
50	Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 102.	5.4	11
51	Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Bioorganic and Medicinal Chemistry, 2011, 19, 429-439.	3.0	10
52	CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization. Molecular Cancer Therapeutics, 2022, 21, 821-830.	4.1	4
53	Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle, 2009, 8, 3652-3656.	2.6	3
54	Resistance Mechanisms to AZD9291 and Rociletinibâ€”Response. Clinical Cancer Research, 2017, 23, 3967-3968.	7.0	3

#	Article	IF	Citations
55	Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. JCO Precision Oncology, 2018, 2, 1-6.	3.0	2